XNASSABSW
Market cap37mUSD
Jan 08, Last price
0.13USD
1D
32.90%
1Q
254.40%
IPO
-91.14%
Name
SAB Biotherapeutics Inc
Chart & Performance
P/E
—
P/S
0.55
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2m
-90.63%
Net income
-42m
L+125.14%
CFO
-25m
L
Earnings
Mar 26, 2025
Profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 2,239 -90.63% | 23,904 -60.73% | |||
Cost of revenue | 40,314 | 56,114 | |||
Unusual Expense (Income) | |||||
NOPBT | (38,075) | (32,209) | |||
NOPBT Margin | |||||
Operating Taxes | 26 | ||||
Tax Rate | |||||
NOPAT | (38,075) | (32,235) | |||
Net income | (42,194) 125.14% | (18,741) 7.43% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 67,164 | (5,444) | |||
BB yield | -176.93% | 21.20% | |||
| Debt | |||||
Debt current | 2,655 | 1,396 | |||
Long-term debt | 8,910 | 9,147 | |||
Deferred revenue | |||||
Other long-term liabilities | 11,774 | 321 | |||
Net debt | (45,001) | (4,504) | |||
| Cash flow | |||||
Cash from operating activities | (25,119) | 3,759 | |||
CAPEX | (197) | (10,944) | |||
Cash from investing activities | (153) | (10,944) | |||
Cash from financing activities | 66,773 | 34,120 | |||
FCF | (34,420) | (29,626) | |||
| Balance | |||||
Cash | 56,566 | 15,047 | |||
Long term investments | |||||
Excess cash | 56,454 | 13,852 | |||
Stockholders' equity | (90,036) | (47,865) | |||
Invested Capital | 165,819 | 85,122 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 5,521 | 4,352 | |||
Price | 6.88 16.55% | 5.90 -92.45% | |||
Market cap | 37,960 47.85% | 25,675 -87.98% | |||
EV | (7,041) | 21,172 | |||
EBITDA | (34,330) | (30,556) | |||
EV/EBITDA | 0.21 | ||||
Interest | 315 | 302 | |||
Interest/NOPBT | |||||